Detection of Specific Genetic Abnormalities by Fluorescence in Situ Hybridization in Soft Tissue Tumors
Overview
Authors
Affiliations
For the detection of chromosome translocations/chimeric genes and specific genetic abnormalities in soft tissue tumors, we conducted fluorescence in situ hybridization (FISH) analysis on 280 cases of soft tissue and other tumors using formalin-fixed paraffin-embedded tissue sections. The detection rate of the FISH split-signal was 84% (129/154 cases) for the translocation-associated soft tissue tumors, such as Ewing's sarcoma/primitive neuroectodermal tumor, synovial sarcoma, alveolar rhabdomyosarcoma, myxoid liposarcoma, clear cell sarcoma and so forth. Positive split-signals from EWSR1, SS18 and FOXO1A probes were detected in 3% (2/64) of various histological types of carcinoma, lymphoma, melanoma, meningioma and soft tissue tumors. In FISH using the INI1/CEP22 probe, the INI1 deletion signal was detected in 100% (9/9) of epithelioid sarcoma. In well-differentiated and dedifferentiated liposarcomas, detection of MDM2 amplification signals in FISH using the MDM2/CEP12 probe were both as high as 85% (11/13) and 100% (13/13), respectively. In other adipocytic and non-adipocytic tumors requiring differentiation from these types, detection was only 13% (5/39), and CEP12 polysomy was frequently detected. As these results demonstrate the high sensitivity and specificity of FISH, we concluded FISH to be a useful pathological diagnostic adjunct for definite and differential diagnosis of soft tissue tumors.
Yu Q, Zhang C, Huang W, Li L Exp Ther Med. 2021; 22(6):1480.
PMID: 34765021 PMC: 8576618. DOI: 10.3892/etm.2021.10915.
Kulac I, Bulutay P, Mericoz C Turk Patoloji Derg. 2021; 37(3):226-232.
PMID: 34514574 PMC: 10510605. DOI: 10.5146/tjpath.2021.01544.
Suzuki H, Mikuni N, Sugita S, Aoyama T, Yokoyama R, Suzuki Y Neurol Med Chir (Tokyo). 2020; 60(3):147-155.
PMID: 32009124 PMC: 7073702. DOI: 10.2176/nmc.oa.2019-0218.
TP53 in bone and soft tissue sarcomas.
Thoenen E, Curl A, Iwakuma T Pharmacol Ther. 2019; 202:149-164.
PMID: 31276706 PMC: 6746598. DOI: 10.1016/j.pharmthera.2019.06.010.
Segawa K, Sugita S, Aoyama T, Kubo T, Asanuma H, Sugawara T Diagn Pathol. 2018; 13(1):73.
PMID: 30219084 PMC: 6138919. DOI: 10.1186/s13000-018-0752-6.